Literature DB >> 24351096

Joint diabetes thalassaemia clinic: an effective new model of care.

Ploutarchos Tzoulis1, Farrukh Shah, Romilla Jones, Emma Prescott, Maria Barnard.   

Abstract

Diabetes is a significant complication of β-thalassemia major (β-TM) and most patients receive fragmented diabetes care. In 2005, we developed a unique Joint Diabetes Thalassaemia Clinic, based at the Department of Diabetes, Whittington Health, London, UK, where patients were reviewed jointly by a multidisciplinary team, including Consultant Diabetologist and Hematologist. Study of the Joint Diabetes Thalassaemia Clinic (2005-2009) showed improvement in glycemic control with fructosamine reduction from 344 umol/L to 319 umol/L over a 1-year period as well as improvement in lipid profiles. The proportion of patients attending the Joint Clinic who achieved metabolic targets compared to the National Diabetes Audit for England was higher for glycemic control (73.0 Joint Diabetes Thalassaemia Clinic vs. 63.0% nationally), blood pressure control (58.0 Joint Diabetes Thalassaemia Clinic vs. 30.0% nationally) and cholesterol control (81.0 Joint Diabetes Thalassaemia Clinic vs. 78.0% nationally). Five patients (22.7%) had microvascular complications. A significant proportion of our patients had endocrinopathies (86.0% hypogonadism, 18.0% hypothyroidism, 23.0% hypoparathyroidism). The unique partnership of our Joint Diabetes Thalassaemia Clinic, allowed these very complex patients to be managed effectively.

Entities:  

Mesh:

Year:  2013        PMID: 24351096     DOI: 10.3109/03630269.2013.862541

Source DB:  PubMed          Journal:  Hemoglobin        ISSN: 0363-0269            Impact factor:   0.849


  4 in total

1.  Characterization of thalassemia major and diabetes mellitus patients at a reference center in Brazil.

Authors:  Gabriela Marsola Olivatto; Carla Regina de Souza Teixeira; Marcela Ganzella Sisdelli; Maria Lúcia Zanetti; Renata Cristina de Campos Pereira Silveira; Claudio Vinicius Gonçalves
Journal:  Hematol Transfus Cell Ther       Date:  2018-12-31

2.  The clinical characteristics, biochemical parameters and insulin response to oral glucose tolerance test (OGTT) in 25 transfusion dependent β-thalassemia (TDT) patients recently diagnosed with diabetes mellitus (DM).

Authors:  Vincenzo De Sanctis; Ashraf Soliman; Ploutarchos Tzoulis; Shahina Daar; Mehran Karimi; Mohamed A Yassin; Gabriella Pozzobon; Christos Kattamis
Journal:  Acta Biomed       Date:  2022-01-19

3.  Screening for glucose dysregulation in β-thalassemia major (β-TM): An update of current evidences and personal experience.

Authors:  Vincenzo De Sanctis; Shahina Daar; Ashraf T Soliman; Ploutarchos Tzoulis; Mehran Karimi; Salvatore Di Maio; Christos Kattamis
Journal:  Acta Biomed       Date:  2022-03-14

4.  The The use of oral glucose-lowering agents (GLAs) in β-thalassemia patients with diabetes: Preliminary data from a retrospective study of ICET-A Network.

Authors:  Vincenzo De Sanctis; Ashraf Soliman; Ploutarchos Tzoulis; Shahina Daar; Antonis Kattamis; Polyxeni Delaporta; Mehran Karimi; Mohamed A Yassin; Tahereh Zarei; Forough Saki; Katia Sapunarova; Atanas Banchev; Maria Concetta Galati; Giuseppe Raiola; Giuseppe Messina; Saveria Campisi; Christos Kattamis
Journal:  Acta Biomed       Date:  2022-05-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.